Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 2/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | HPD | P32754 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.46 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.46 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | PRKDC | P78527 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30317738 | 1.00 | MAOB (0.49) | MAOBBRD4MRGPRX4BCHECYP4F2 | |
| SCHEMBL22816808 | 0.84 | GSTP1 (0.50) | MAOBBCHEHTR1A | |
| SCHEMBL9353033 | 0.84 | ALOX5 (0.48) | PRMT5WDR77ALOX5 | |
| SCHEMBL2572521 | 0.81 | PRMT5 (0.46) | PRMT5WDR77HTR1A | |
| SCHEMBL10041855 | 0.81 | MAOB (0.50) | MAOBBCHEMAOA | |
| SCHEMBL9214604 | 0.80 | FABP7 (0.51) | MAOBBRD4MRGPRX4BCHECYP4F2 | |
| SCHEMBL3540686 | 0.80 | MAOB (0.46) | MAOBBRD4MRGPRX4BCHECYP4F2 | |
| SCHEMBL17072360 | 0.79 | GSTP1 (0.49) | MAOBBCHEMAOA | |
| SCHEMBL379281 | 0.79 | MAOB (0.67) | MAOBMRGPRX4BCHECYP4F2CYP4A11 | |
| SCHEMBL2137838 | 0.78 | MRGPRX4 (0.69) | MAOBMRGPRX4BCHECYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| CN-110804072-B | Dioxolane analogues of uridine for use in the treatment of cancer | 美迪维尔公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-110790789-B | Dioxolane analogues of uridine for use in the treatment of cancer | 美迪维尔公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-04-20 | — | — | US | disclosed |
| US-11447511-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2022-09-20 | — | — | US | disclosed |
| EP-3572410-B1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2022-07-20 | — | — | EP | disclosed |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2021-02-25 | — | — | US | disclosed |
| US-10822360-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2020-11-03 | — | — | US | disclosed |
| US-20200239502-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2020-07-30 | — | — | US | disclosed |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-06-25 | — | — | US | disclosed |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-06-25 | — | — | US | disclosed |
| WO-2015056213-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015034420-A1 | HCV POLYMERASE INHIBITORS | MEDIVIR AB (SE) | 2015-03-12 | — | — | WO | disclosed |
| EP-1420771-B9 | USE OF TRIFLUOROACETYL ALKYL-SUBSTITUTED PHENYL DERIVATIVES, PHENOL DERIVATIVES, AND BENZOYL DERIVATIVES IN THE TREATMENT AND/OR PROPHYLAXIS OF OBESITY AND ACCOMPANYING DISEASES AND/OR SECONDARY DISEASES | SOLVAY PHARM GMBH (DE) | 2007-10-17 | — | — | EP | disclosed |
| EP-1420771-B1 | USE OF TRIFLUOROACETYL ALKYL-SUBSTITUTED PHENYL DERIVATIVES, PHENOL DERIVATIVES, AND BENZOYL DERIVATIVES IN THE TREATMENT AND/OR PROPHYLAXIS OF OBESITY AND ACCOMPANYING DISEASES AND/OR SECONDARY DISEASES | SOLVAY PHARM GMBH (DE) | 2006-09-06 | — | — | EP | disclosed |
| US-6930207-B2 | Trifluoroacetylalkyl-substituted phenyl, phenol and benzoyl compounds and related methods of treatment | SOLVAY PHARMACEUTICAL GMBH (DE) | 2005-08-16 | — | — | US | disclosed |
| US-20040214901-A1 | Trifluoroacetylalkyl-substituted phenyl, phenol and benzoyl compounds and related methods of treatment | SOLVAY PHARMACEUTICALS GMBH (DE) | 2004-10-28 | — | — | US | disclosed |
| EP-1420771-A2 | USE OF TRIFLUOROACETYL ALKYL-SUBSTITUTED PHENYL DERIVATIVES, PHENOL DERIVATIVES, AND BENZOYL DERIVATIVES IN THE TREATMENT AND/OR PROPHYLAXIS OF OBESITY AND ACCOMPANYING DISEASES AND/OR SECONDARY DISEASES | Solvay Pharmaceuticals GmbH (DE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003007923-A2 | USE OF TRIFLUOROACETYL ALKYL-SUBSTITUTED PHENYL DERIVATIVES, PHENOL DERIVATIVES, AND BENZOYL DERIVATIVES IN THE TREATMENT AND/OR PROPHYLAXIS OF OBESITY AND ACCOMPANYING DISEASES AND/OR SECONDARY DISEASES | SOLVAY PHARMACEUTICALS GMBH (DE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239502-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | MAOB 453/4885BRD4 1841/4885MRGPRX4 2314/4885 |
| US-20040214901-A1 | Trifluoroacetylalkyl-substituted phenyl, phenol and benzoyl compounds and related methods of treatment | PNLIP, LIPC, CEL | MAOB 334/4885BRD4 305/4885MRGPRX4 2383/4885 |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NT5C | MAOB 407/4885BRD4 1730/4885MRGPRX4 2233/4885 |
| US-20150175648-A1 | HCV POLYMERASE INHIBITORS | POLI, POLB, POLL | MAOB 353/4885BRD4 1911/4885MRGPRX4 3140/4885 |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | MAOB 453/4885BRD4 1841/4885MRGPRX4 2314/4885 |
| US-11447511-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | MAOB 453/4885BRD4 1841/4885MRGPRX4 2314/4885 |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | MAOB 453/4885BRD4 1841/4885MRGPRX4 2314/4885 |
| US-10822360-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | MAOB 453/4885BRD4 1841/4885MRGPRX4 2314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.